Related CAS #
26020-55-3 (free base); 34522-46-8 (fumarate)
Synonym
Oxetorone Free Base; Oxetorona; Oxetoronum
IUPAC/Chemical Name
3-(12H-Benzofuro(3,2-c)(1)benzoxepin-6-yliden)-N,N-dimethylpropylamin
InChi Key
VZVRZTZPHOHSCK-LICLKQGHSA-N
InChi Code
InChI=1S/C21H21NO2/c1-22(2)13-7-10-17-15-8-3-5-11-19(15)23-14-18-16-9-4-6-12-20(16)24-21(17)18/h3-6,8-12H,7,13-14H2,1-2H3/b17-10+
SMILES Code
CN(C)CC/C=C1C(OC2=CC=CC=C23)=C3COC4=CC=CC=C/14
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
319.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Macaigne G, Boivin JF, Chayette C, Cheaib S, Deplus R. Colite lymphocytaire associée à la prise d'oxétorone [Oxetorone-associated lymphocytic colitis]. Gastroenterol Clin Biol. 2002 May;26(5):537. French. PMID: 12122372.
2: Deguigne M, Bruneau C, Touré A, Turcant A, Le Roux G. New evidence for oxetorone toxicity. Clin Toxicol (Phila). 2017 Feb;55(2):142-146. doi: 10.1080/15563650.2016.1267358. Epub 2016 Dec 14. PMID: 27967233.
3: Pradalier A, Molitor JL, Campinos C. Oxétorone et sueurs profuses [Oxetorone and profuse sweating]. Therapie. 2003 Mar-Apr;58(2):166-7. French. doi: 10.2515/therapie:2003025. PMID: 12942859.
4: Payen C, Patat AM, Pulce C, Descotes J. Intoxication aiguë par oxetorone [Acute poisoning with oxetorone]. Therapie. 2006 Nov-Dec;61(6):548-50. French. doi: 10.2515/therapie:2006081. PMID: 17348615.
5: Pradalier A. Hyperprolactinaemia and depression induced by oxetorone. Cephalalgia. 1996 Dec;16(8):560-1. doi: 10.1046/j.1468-2982.1996.1608560.x. PMID: 8980859.
6: Fathallah N, Chatti S, Azouz MM. Colite lymphocytaire associée à la prise d'oxétorone [Lymphocytic colitis associated with oxetorone consumption]. Gastroenterol Clin Biol. 2010 Feb;34(2):154-5. French. doi: 10.1016/j.gcb.2009.12.001. Epub 2010 Jan 21. PMID: 20096517.
7: Galerneau V, Petit J, Deghmani M, Leroy J, Droy JM, Leroy A, Oksenhendler G, Winckler C. Severe self-poisoning with oxetorone: report of one case. J Toxicol Clin Toxicol. 1990;28(1):111-6. doi: 10.3109/15563659008993482. PMID: 2381017.
8: Roos C. Migraine : données épidémiologiques, cliniques et thérapeutiques [Migraine epidemiological, clinical and therapeutic data]. Biol Aujourdhui. 2019;213(1-2):35-41. French. doi: 10.1051/jbio/2019019. Epub 2019 Jul 5. PMID: 31274101.
9: Barchewitz G, Vernant C, Mazue G, Binon F, Cier A, Tuchmann Duplessis H. Oxetorone-induced hyperprogesteronemia and the development of uterine decidual lesions in rats. Arzneimittelforschung. 1984;34(9):1007-10. PMID: 6542368.
10: de Coster J. Etude de l'oxétorone dans les céphalées migraineuses [Oxetorone in the treatment of migrainous cephalalgia (author's transl)]. Schweiz Rundsch Med Prax. 1976 Jul 13;65(28):879-82. French. PMID: 1005299.
